

(43) International Publication Date
3 July 2014 (03.07.2014)

(51) International Patent Classification:
C07D 237/32 (2006.01) *C07D 498/04* (2006.01)
C07D 487/04 (2006.01) *C07D 513/04* (2006.01)
C07D 491/048 (2006.01) *A61K 31/502* (2006.01)
C07D 495/04 (2006.01) *A61P 35/00* (2006.01)

(74) Agents: **SUBRAMANIAM, Hariharan** et al.; Subramaniam & Associates, Central Square, Suite-328, Plaza III, 20 Manoharlal Khurana Marg, Bara Hindu Rao, (off Rani Jhansi Road), Delhi - 110006 (IN).

(21) International Application Number:
PCT/IN2013/000794

(22) International Filing Date:
23 December 2013 (23.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
3742/MUM/2012 31 December 2012 (31.12.2012) IN

(71) Applicant: **CADILA HEALTHCARE LIMITED** [IN/IN]; Zydus Tower, Satellite Cross Roads, Ahmedabad 380015, Gujarat (IN).


(72) Inventors: **SRIVASTAVA, Brijesh, K.**; Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads, Ahmedabad 380015, Gujarat (IN). **DESAI, Ranjit, C.**; Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads, Ahmedabad 380015, Gujarat (IN). **PATEL, Pankaj, R.**; Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads, Ahmedabad 380015, Gujarat (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1



(I)

(57) Abstract: The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis. The compounds of formula (I) are useful as PARP-1 inhibitors for the treatment of, e.g. cancer.



Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*


Published:

- *with international search report (Art. 21(3))*

SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1

FIELD OF THE INVENTION

The present invention relates to novel compounds of general formula (I), their 5 stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to processes for preparing the novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions 10 containing them, and novel intermediates involved in their synthesis.



(I)

The present invention is further directed to compounds which cause selective inhibition of the poly (ADP-ribose) polymerase-1.

15

BACKGROUND & PRIOR ART

Exploitation of synthetic lethal relationship is a trustworthy therapeutic strategy to target genetic differences between tumor and normal cells which eventually provide large therapeutic window for the treatment of cancer. Poly (ADP-ribose) polymerase-1(PARP-1, 113 kDa) is a prototype member of the 17 member PARP protein superfamily. PARP-1 is a nuclear protein whose zinc finger DNA binding domain localizes PARP-1 to the site of DNA damage. This NAD dependent enzyme catalyzes 20 poly (ADP-ribosylation) of proteins, involved in the detection and repair of DNA damage. It plays a frontal role in the decision of a cell to live or to die in a stress situation [Senthil kumar B., Rajmohan, *et al.*, *Mol. Cell. Biol.* 2009, 29(15), 4116-25 4129]. The primary structure of the enzyme is highly conserved in eukaryotes with

human enzyme having 92% homology with mouse enzyme at the level of amino acid sequence and a 50 amino acid block showing 100% homology between vertebrates [Virag Laszlo and Szabo Csaba, *Pharmacol. Reviews* 2002, 54(3), 375-429]. Studies on the molecular mechanism of PARP-1 suggests that, it is involved in various DNA related functions including gene amplifications, cell division, differentiation, apoptosis, DNA base excision repair and also effects on telomere length and chromosome stability [d'Add di Fagagna *et al.*, *Nature Gen.* 1999, 23(10), 76-80]. It has been reported that PARP-1 modulates DNA repair and other processes and can produce long chains of poly (ADP-ribose) within the cell nucleus which is central to its activity [Althaus, F. R.; Richter, C. *Mol. Biol., Biochem. Biophys.* 1987, 37, 1-237]. Different studies on knock out mouse models, report that the deletion of PARP-1 impairs DNA repair but is not embryonically lethal. Double knock out PARP-1 and PARP-2 mice die during early embryogenesis, which shows that PARP-2 as the closest homolog of PARP-1 (62% identical in its catalytic domain to PARP-1) & plays a major role in the DNA repair during the absence of PARP-1 enzyme [Ratnam Kapil and Law Jenifer A. *Clin. Cancer Res.* 2007, 17(5), 1383-1388]. A group of scientists from Newcastle University and University of Konstanz, in *British Journal of Cancer* 2009, 101(2), 256 – 26, claims to be the first to directly compare PARP-1 polymorphisms, cellular levels of PARP-1 protein and PARP activity in a systematic way and reveals that PARP activity depends on other factors beside the level of protein and the active site SNP.

In a recent review from *Free Radical Biology & Medicine* 2009, 47, 13–26 suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers, but also as single agents to selectively kill cancers which are due to defect in DNA repair, specifically cancers with mutations in the breast cancer-associated gene (BRCA1 and BRCA2). PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues. The activation of PARP may also induce various cell death processes and promotes an inflammatory response associated with multiple organ failure.

Recently some of the investigators have demonstrated in *Biochem. Pharmacol.* 2009, 77, 1348–1357 that PARP inhibitors combined with DNA-damage inducing cytostatic

agents like taxol can lead to effective tumor therapy through activation of PI-3-kinase-Akt pathway.

The American Society of Clinical Oncology held its Annual Meeting in Orlando,

Florida (May 29–June 2, 2009) and as reported in *Eur. J. Cancer* 2009, 45, 1897 –

5 1901 that two drugs Olaparib and BSI-201 from a new class of targeted agents called poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated significant activity against hard-to treat breast cancers, according to findings from two separate phase II trials.


Several small molecules that specifically target PARP-1 enzyme as an inhibitor are

10 being investigated and among them BSI 201 (BiPar) is in Phase III clinical trial and AG 14699 (Cancer Res. UK), AZD 2281 (KuDOS), ABT 888 (Abbott) are in Phase II clinical trial, with promising initial results. However, special attention must be paid to the possibility that enhanced therapeutic efficacy might be accompanied by increased off-target effects because of effect on DNA-repair mechanism in normal tissues.


15 Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets as described in *Nature Reviews Cancer* 4 March 2010, 1–9. Crystal Structure of the Catalytic Domain of Human PARP2 in Complex with PARP Inhibitor ABT-888 reported by [Herwig Schuler *et al.*, *Pharmacol. Biochemistry* 2010, 49, 1056–1058]

20 Novel compounds which are selective PARP-1 inhibitors, their preparation and their use in medicine have also been reported in WO 2002036576, WO 2006039545, WO 2007062413, WO 2004080976, WO 2009093032, WO 2008047082, WO 2001042219, WO 2005066163, WO 2006106326, WO 2008146035, WO 2006021801, US 20090192156, WO 2012019427, WO 2012071684, WO

25 2012019426, WO 2012072033, which are incorporated as references in their entirety. Synthesis of phthalazinone derivatives of the following general formula and having the potential to inhibit PARP for the treatment of cancer or for potentiating tumor cells for the treatment with ionizing radiation or chemotherapeutic agents has been disclosed in US 2009/0192156 A1 and WO 2009/093032 A1.




Synthesis of thiophene carboxamide class of compounds as the combination of CHK and PARP inhibitors for the treatment of cancer is disclosed in WO 2008146035 A1 and WO 2005066163 A2. Representative compounds have the following general formula,




Wherein X is selected from NH, S and O. Y is selected from CH or N.


Crystalline form and improved method for the synthesis of particular pthalazinone derivatives and use of the crystalline form as PARP-1 inhibitor has been reported in WO 2008047082. Representative compounds have the following structure:




Synthesis of 4-heteroaryl methyl substituted pthalazinone derivatives has been disclosed in WO 2006021801 A1 and WO 2004080976 A1 for use in treating cancer or other diseases ameliorated by the inhibition of PARP.



wherein, A and B together represent an optionally substituted, fused aromatic ring; X can be NR^X or $CR^X R^Y$; If $X=NR^X$ then n is 1 or 2 and if $X=CR^X R^Y$ then n is 1; R^X is selected from the group consisting of H, optionally substituted C_{1-20} alkyl, C_{1-20} aryl, $C_{(3-20)}$ heterocyclyl, thioamido, ester, acyl, and sulfonyl groups; R^Y is selected from H, hydroxyl, amino; R^X and R^Y may together form a spiro C_{3-7} cycloalkyl or heterocyclyl group; R^{C1} and R^{C2} are independently selected from the group consisting of H and C_{1-4} alkyl; R^1 is selected from H and halo; And Het is selected from



where Y^1 is selected from CH and N, Y^2 is selected from CH and N, Y^3 is selected from CH, CF and N, where one or two of Y^1 , Y^2 , and Y^3 can be N; and



wherein Q is O or S.


Optimization of Phenyl-Substituted Benzimidazole Carboxamide Poly(ADP-Ribose) 5-Benzamidoisoquinolin-1-ones and 5-(ω -Carboxyalkyl)isoquinolin-1-ones as Isoform-Selective Inhibitors of Poly(ADP-ribose) Polymerase 2 (PARP-2) has been described in *J. Med. Chem.* **2011**, *54*, 2049-2059 by Peter T. Sunderland *et. al.* Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts has been recently published in *Clin Cancer Res* **2011**, *17*, 783-791.

Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry has been described in *Journal of Chromatography B*, **2011**, *878*, 333-339.


“Evolution of Poly(ADP-ribose)Polymerase-1(PARP-1) inhibitors, From Concept to Clinic” a review article by Dana V. Ferraris has been published in *J. Med. Chem.* **2010**, *53*, 4561-4584, which describes in details of the efforts by different pharmaceutical industries and academic institutions in the development of the PARP 1 inhibitors.

“Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3-(2H)-ones as potent poly(ADP-ribose)polymerase -1(PARP-1) inhibitors active in BRCA deficient cells” article has been published by Federica Ferrigno et al. in *Bioorg. Med. Chem. Lett.* **2010**, *20*, 1100-1105.

5 ‘Polymerase Inhibitors: Identification of (S)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly Potent and Efficacious Inhibitor’ has been described in *J. Med. Chem.*, **2010**, *53*, 3142–3153.




10 Design, synthesis of Quinoline-8-carboxamides; a new class of Poly (adenosine-diphosphate-ribose) polymerase-1 (PARP-1) Inhibitor has been described in *J. Med. Chem.* **2009**, *52*, 868–877. Synthesis of 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide as a Poly (ADP-ribose) Polymerase (PARP) Inhibitor has been disclosed in *J. Med. Chem.* **2009**, *52*, 514–523.




15

Synthesis of aminoethyl pyrrolo dihydroisoquinolinones as novel poly (ADP-ribose) polymerase-1 inhibitors has been described in *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4042–4045. Representative compounds have the following general formula.




20

Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors has been described in *Bioorg. Med. Chem. Lett.* 2009, 19, 7537–7541. Representative compounds have the following general formula.




5

Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors has been described in *Bioorg. Med. Chem. Lett.* 2009, 19, 4196–4200. Representative compounds have the following general formula




10

Synthesis of novel tricyclic quinoxalinone as the inhibitors of poly (ADP-ribose) polymerase-1 (PARP-1) has been stated in *Bioorg. Med. Chem. Lett.* 2009, 19, 4050–4054. Representative compounds have the following general formula.





15 Identification of ring-fused pyrazolo pyridin-2-ones as novel poly (ADP-ribose) polymerase-1 inhibitors has been published in *Bioorg. Med. Chem. Lett.* 2008, 18, 5126–5129. This describes compounds of the following general formula.




Discovery of Orally Active and Brain-Penetrable Quinoxalinone Inhibitors of Poly (ADP-ribose) polymerase has been disclosed in *J. Med. Chem.* 2004, 47, 4151-4154 and describes compounds of the following general formula.

5




Discovery of potent Poly(ADP-ribose) Polymerase-1 Inhibitors from the modification of Indeno[1,2-c]isoquinolinone and the described compounds of the following general formula I has been reported in *J. Med. Chem.* 2005, 48, 5100-5103.

10



(1)


WO 2012 019426 discloses PARP inhibitors of the following general formula (I)



(I)

wherein: A and B are connected together to the carbon atoms to form a cycloalkyl group, heterocyclic group, aryl or heteroaryl group, Each of the ring atoms D or E is independently selected from C or N atoms; when n is 1, D and E are connected to one another to accomplish 6 ~ 10-membered ring X; This specification is incorporated as reference in its entirety.


5 WO 2012 072033 discloses compounds of formula I or II, their isomers, salts, solvates, chemically protected form, and prodrugs:




10 wherein the substituents are as defined in the specification which is incorporated in entirety as reference.

New Gen Therapeutics, Inc has published a patent WO 2012166983 and disclosed tricyclic inhibitors of poly(ADP-ribose)polymerase.

15 Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as Poly (ADP-ribose) polymerase-1 inhibitors has been published in WO 2012014221 by Cadila Healthcare Ltd. and discloses the following general structure




20 Shanghai Institute of Materia Medica, Chinese Academy of Science disclosed 2-Arylfuran-7-formamide compounds preparation method and use thereof in patent WO 2013117120 and mentions the following formula:



(I)


Merck disclosed tetrahydro-quinazolinone derivatives as tankyrase and PARP inhibitors in patent WO 2013/117288 and mentions the following general structure

5



(I)

Novel compounds having PARP inhibitory activity has been disclosed by Santen Pharmaceutical Co. Ltd. in a patent WO 2013/008872 and the following formula has been disclosed.




(I)

10

Fused tetra or penta- cyclic pyridophthalazinones as PARP inhibitors have been reported by Belgena, Ltd. in a patent WO 2013097226.

AstraZeneca AB has published a patent US 8475842 for immediate release pharmaceutical formation of 4-[3-4(cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one.

15 BioMarin recently published a patent US 2013/0053365 and disclosed the formula (M)




formula (M)

Though several compounds have been reported in the literature as PARP-I inhibitors, very few have actually shown actual clinical benefits and none have been approved so far. Looking at the large unmet medical needs, there appears a need for developing 5 further compounds which have better safety and efficacy profile. We herein disclose a new series of compounds which shows potential as PARP-I inhibitors.

SUMMARY OF THE INVENTION

The present invention describes novel compounds useful as poly (ADP-ribose) 10 polymerase-1 inhibitors. The compounds are defined by the general formula (I) below.




(I)

The compounds of the present invention acts by inhibiting PARP1 enzyme to prevent the process of DNA repair and induce cell mediated apoptosis. As a result of 15 compromised repair, PARP-1 deficient or inhibited cells are more sensitive to DNA damaging agents (γ radiation, topoisomerase inhibitors, and alkylating agents). The compounds of the present invention are selective inhibitors of the poly (ADP-ribose) polymerase-1.

OBJECTS OF THE INVENTION

The main object of the present invention is to provide novel compounds of general formula (I), their stereoisomers, tautomeric forms, their regioisomers, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures and their use in medicine.




(I)

Another object of the present invention is provided a process for the preparation of novel compounds of general formula (I), their stereoisomers, regioisomers and their tautomeric forms, novel intermediates involved in their synthesis, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

Another object of the present invention is to provide a method of treatment of diseases which can be treated or whose symptoms can be reversed with by administering a therapeutically effective & non-toxic amount of the compound of formula (I) or their pharmaceutically acceptable compositions to the mammals.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention are defined by the general formula (I) below:



(I)

wherein 'A' and 'B' may be independently selected from hydrogen, alkyl or connected together to the carbon atoms to form a cycloalkyl, heterocyclyl, aryl or heteroaryl groups, wherein each of the said cycloalkyl, heterocyclyl, aryl or heteroaryl groups are further substituted independently by one or more substituent groups selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, 5 aryl, heteroaryl, -C(O)OR⁵, -OC(O)R⁵, -O(CH₂)_pC(O)OR⁵, -C(O)R⁵, -NHC(O)R⁵, -NR⁶R⁷, -OC(O)NR⁶R⁷ or -C(O)NR⁶R⁷ groups.

R¹ at each occurrence is independently selected from H, halogen, or the groups selected from (C₁-C₁₂)alkyl, haloalkyl, cycloalkyl, alkylthio or the group (OSO₂)alkyl, wherein each of these groups may be further substituted by suitable substituents selected from those disclosed hereinafter below; m = 1-4;

L = -O, -S, -NH;

R² is selected from substituent groups consisting of hydrogen atom, hydroxyl, alkyl, cycloalkyl, oxo, C(O)OR⁵, -C(O)R⁵, or -C(O)NR⁶R⁷, wherein said alkyl or cycloalkyl group may be further substituted by one or more substituents groups selected from halogen, hydroxyl, alkyl or alkoxy. 15

R³ and R⁴ are each independently selected from the groups such as hydrogen atom, alkyl, hydroxyl, alkoxy, cycloalkyl, -C(O)OR⁵, -OC(O)R⁵, -O(CH₂)_pC(O)OR⁵, -C(O)R⁵, -NHC(O)R⁵, -NR⁶R⁷, -OC(O)NR⁶R⁷ or -C(O)NR⁶R⁷; alternatively, R³ and 20 R⁴ together form an oxo group;

Each of ring atoms 'D' and 'E' is independently selected from C or N atoms; 'D' and 'E' are connected to one another to form 5 membered ring 'X', wherein 'X' is selected from the groups such as cycloalkyl, heterocyclyl, heteroaryl, wherein the cycloalkyl, heterocyclyl or heteroaryl groups is further substituted with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, 25 aryl or heteroaryl, benzyl, oxo, OR⁵, -C(O)OR⁵, -OC(O)R⁵, -O(CH₂)_pC(O)OR⁵, C(O)R⁵, S(O)_nR⁵, -NHC(O)R⁵, NR⁶R⁷, -OC(O)NR⁶R⁷ or -C(ONR⁶R⁷), wherein the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or benzyl are each independently substituted further with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -C(O)OR⁵, -OC(O)R⁵, -O(CH₂)_pC(O)OR⁵, -C(O)R⁵, -S(O)_nR⁵, -NHC(O)R⁵, NR⁶R⁷, -OC(O)NR⁶R⁷ or -C(O)NR⁶R⁷ substituents; 30

5 R^5 at each occurrence is independently selected from hydrogen atom, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups; wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups are each independently substituted by one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents.


10 Each of R^6 or R^7 at each occurrence are independently selected from the groups consisting of hydrogen atom, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups; wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups are each independently further substituted by one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents;

15 Alternatively, R^6 and R^7 are joined together with nitrogen atom to form a heterocyclic ring; wherein said heterocyclic ring contains one or more heteroatoms selected from N, O, S(O)_n, furthermore the stated heterocyclic ring is further substituted with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituted substituents;

n is 0, 1 or 2 and p is 0, 1 or 2.


20 Suitable substituents wherever applicable and where substituents are not specifically mentioned includes, but are not limited to the following radicals, alone or in combination with other radicals, hydroxyl, oxo, halo, thio, nitro, amino, alkyl, alkoxy, haloalkyl or haloalkoxy groups.

The preferred heterocycles representing



25

may be selected from the following bicyclic rings mentioned below



In another preferred embodiment, the groups representing the above may further be selected from those described hereinafter.

The “aryl” may be selected from phenyl, naphthyl, tetrahydronaphthyl, indenyl, 5 dihydroindenyl, biphenyl groups and each of these groups may be optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, cyano, thioalkyl, cycloalkyl groups; “Heteroaryl” or “heteroaromatic” is selected from suitable single or fused mono, bi or tricyclic aromatic heterocyclic radicals containing one or more hetero atoms selected 10 from O, N or S, more preferably the groups are selected from pyridyl, thienyl, furyl, pyrrolyl, indolinyl, indolyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, purinyl groups, each of these groups may be further optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, 15 cyano, alkylthio, thioalkyl groups; “Heterocyclyl” may be selected from suitable saturated, partially saturated or unsaturated aromatic or non-aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms selected from nitrogen, sulfur and oxygen, more preferably selected from aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2-oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, 20 thiomorpholinyl, 2-oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazolidinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzodihydrofuryl, benzodihydrothienyl, pyrazolopyrimidonyl, azaquinazolinoyl, thienopyrimidonyl,

quinazolonyl, pyrimidonyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, thienopiperidinyl groups, each of these groups may be optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups;

5 In a further embodiment the groups, radicals described above may be selected from:

- the term "alkyl" used either alone or in combination with other radicals, denotes a linear or branched radical containing one to six carbons, selected from methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *tert*-butyl, amyl, *t*-amyl, *n*-pentyl, 10 *n*-hexyl, and the like;
- the term "alkoxy" used either alone or in combination with other radicals, is selected from groups containing an alkyl radical, as defined above, attached directly to an oxygen atom, more preferably groups selected from methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, *t*-butoxy, *iso*-butoxy, pentyloxy, 15 hexyloxy, and the like;
- the term "haloalkyl" is selected from an alkyl radical, as defined above, suitably substituted with one or more halogens; such as fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl or hexyl groups;
- 20 - "Haloalkoxy" is selected from suitable haloalkyl, as defined above, directly attached to an oxygen atom, more preferably groups selected from fluoromethoxy, chloromethoxy, fluoroethoxy, chloroethoxy and the like;
- the term "alkylthio" used either alone or in combination with other radicals, denotes a straight or branched or cyclic monovalent substituent comprising an alkyl group as defined above, linked through a divalent sulfur atom having a free valence bond from the sulfur atom, more preferably the groups may be selected 25 from methylthio, ethylthio, propylthio;
- the term "aralkyl" represents an aryl group as defined above attached to an alkyl group as described above;
- 30 - "Heteroaralkyl" and "heterocyclalkyl" represents heteroaryl and heterocyclyl groups respectively as defined above attached to an alkyl group as defined above.

The compounds of formula (I) may optionally be converted to their suitable pharmaceutically acceptable salts by processes as are known in the art. The novel compounds of the present invention can further be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by 5 techniques and processes and concentrations as are well known.

The compounds of the present invention modulate PARP-1 receptor and are useful as a therapeutic target for many diseases and especially for the treatment of cancer.

The compounds prepared according to present invention include, but are not limited to:

- 10 Example 1: 4-(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;
- Example 2: 2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydropthalazin-1-yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione;
- Example 3: 4-(4-fluoro-3-(1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one;
- 15 Example 4: 4-(3-(5-(cyclopropanecarbonyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;
- Example 5: 4-(3-(1-(cyclopropylmethyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;
- 20 Example 6: 4-(3-(5-(cyclopropylmethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;
- Example 7: 4-(4-fluoro-3-(5-(2,2,2-trifluoroethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;
- Example 8: 4-(3-(5-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-25 2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;
- Example 9: 4-(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride;
- Example 10: 4-(4-fluoro-3-(5-(2-((3-fluorophenyl)thio)-2-methylpropanoyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;
- 30 Example 11: 2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydropthalazin-1-yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione;

Example 12: 4-(3-(1-(cyclopropanecarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 13: tert-butyl 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl) hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate;

5 Example 14: 4-(4-fluoro-3-(hexahydro-1H-furo[3,4-c]pyrrole-5-carbonyl)benzyl)phthalazin-1(2H)-one;

Example 15: 4-(4-fluoro-3-(octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

10 Example 16: 4-(4-fluoro-3-(5-(methylsulfonyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

Example 17: 4-(4-fluoro-3-(1-(methylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one;

15 Example 18: 4-(3-(5-benzoyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 19: 4-(3-(5-(2,4-difluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 20: 4-(3-(5,6-dihydro-4H-furo[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

20 Example 21: 4-(4-fluoro-3-(5-methyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

Example 22: 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione;

Example 23: 4-(4-fluoro-3-(octahydrocyclopenta[c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

25 Example 24: 4-(4-fluoro-3-(5-(4-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

Example 25: 4-(4-fluoro-3-(5-(2-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

Example 26: 4-(4-fluoro-3-(5-(2-4-(4-fluoro-3-((6-methoxypyridin-2-yl)methyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

30 Example 27: 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)-2-methyltetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione;

Example 28: 4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one compound with 4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one (1:3);

5 Example 29: 4-(3-(2,2-dioxido-3,4,5,6-tetrahydro-1H-thieno[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one;

Example 30: 4-(3-(5,6-dihydro-4H-thieno[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one;

10 Example 31: 4-(4-fluoro-3-(1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

Example 32: 4-(4-fluoro-3-(5-phenyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

Example 33: 4-(4-fluoro-3-(5-methyl-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one;

15 Example 34: 4-(3-((3aR,8bR)-decahydropyrrolo[3,4-a]pyrrolizine-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 35: 4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one;

20 Example 36: 4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one;

Example 37: 2-((5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoyl)hexahydropyrrolo [3,4-c]pyrrol-2(1H)-yl)methyl)-6-methoxypyridine-1-oxide;

Example 38: 4-(3-(5-(difluoromethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one;

25 Example 39: 4-(4-fluoro-3-((3aR,6aS)-5-oxooctahydrocyclopenta[c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one;

Example 40: Mixture of 1 & 2 Ethyl 4-(3-(2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 41: 4-(3-(2-ethyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

30 Example 42: 4-(3-(1-ethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 43: 4-(4-fluoro-3-(1-isopropyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one;

Example 44: Mixture of (1 & 2 isopropyl) 4-(4-fluoro-3-(1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one;

5 Example 45: 4-(4-fluoro-3-(2-isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one;

Example 46: 4-(3-((3a*R*,6a*S*)-5,5-difluoroctahydrocyclopenta[c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

10 Example 47: 4-(4-fluoro-3-(5-(2-methoxyethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one;

Example 48: N-((3a*R*,6a*S*)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)octahydrocyclopenta[c]pyrrol-5-yl)cyclopropanecarboxamide;

Example 50: 4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one hydrobromide;

15 Example 51: 4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one hydrochloride;

Example 52: 4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one sulfate;

20 Example 53: 4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one 4-methylbenzenesulfonate;

Example 53: 4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one benzenesulfonate;

Example 54: 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)-2-isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-2-ium hydrogensulfate;

25 Example 55: 4-(3-(1-cyclopropyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one;


Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.

The compounds of the present invention may be prepared using the methods described below, together with conventional techniques known to those skilled in the art of organic synthesis, or variations thereon as appreciated by those skilled in the art.

Referred methods include, but are not limited to those described below, where all symbols are as defined earlier.

The compounds of the present invention can be prepared according to the following schemes 1

5 **Scheme 1:**



^a Reagents and conditions: , DMF, TBTU, triethylamine, 0-27 °C, 2-6 h

Synthesis of compound of general formula (I)

General process of preparation:

10 The Compounds of the general formula (II) can be synthesized by processes reported for e.g. in *J. Med. Chem.* 2008, 51, 6581-6591 with suitable modifications/alterations as required which are within the skills of a skilled person.

Compounds of the general formula (I) can be synthesized by coupling the compounds of the general formula (III) with the compounds of the general formula (II), using suitable coupling agents such as O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium-tetrafluoroborate(TBTU),dimethylaminopyridine(DMAP),

15 dicyclohexylcarbodiimide (DCC), hydroxybenzotriazole (HOBr.H₂O), and 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC. HCl) & the like in the presence of organic bases such as DIPEA, TEA, pyridine, & the like in the solvents such as tetrahydrofuran, dimethyl formamide, dichloromethane, chloroform & the like or their suitable mixtures at ambient temperature.


20 The invention is further exemplified by the following non-limiting examples which are provided for exemplifying the invention and should not be construed as limiting the scope of the invention in any ways. It will be appreciated that the other embodiments which are not exemplified can be easily practiced by a skilled person

using his routine skills after reading the specific examples provided below. Such changes/alterations/modifications etc. which may be required to practice the full scope of the invention as described and claimed in the present invention are well within the scope of a person skilled in the art.

5 Unless otherwise specified, ^1H NMR spectral data given in the examples are recorded using a 400 MHz spectrometer (Bruker Topspin 2.0) and reported in δ scale. Tetra methyl silane is used as the internal standard.

Example 1

Synthesis of 4-(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one.




To a solution of 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid (1 g, 3.35 mmol) in dry DMF (15 mL) was added TBTU (1.292 g, 4.02 mmol) at room temperature under atmosphere of nitrogen. To this 2-benzyloctahydropyrrolo[3,4-c]pyrrole (0.678 g, 3.35 mmol) and DIPEA (1.32 mL, 6.71 mmol) were added. The reaction mixture was stirred at room temperature for 2 h. The progress of reaction was checked by TLC by using mobile phase 5 % methanol in chloroform. The reaction mixture was diluted with ethyl acetate. The organic layer was washed with water, dried over anhydrous Na_2SO_4 and solvents were evaporated on a rotatory evaporator under reduced pressure to crude solid which was purified by the flash column chromatography using eluent chloroform : methanol (97 : 3) to afford 4-(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one as white solid (1.19 g, 74 %).

$^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 12.59 (s, 1H), 8.25 (dd, $J = 7.6$ Hz & 0.6 Hz, 1H), 7.94 (d, $J = 7.6$ Hz, 1H), 7.86 – 7.80 (m, 2H), 7.35 (m, 1H), 7.32 (dd, 1H), 5.29 – 7.24 (m, 4H), 7.23 – 7.20 (m, 2H), 4.32 (s, 2H), 3.63 (m, 1H), 3.47 (m, 1H), 3.46 (m, 2H), 3.36 (m, 1H), 2.9 (dd, 1H), 2.60 – 2.8 (m, 3H), 2.51 – 2.49 (m, 2H), 2.1 (m, 1H).

Example 2


2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydropthalazin-1-yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione.



15 $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 12.59 (s, 1H), 8.25 (d, $J = 7.6$ Hz, 1H), 7.80-7.89 (m, 3H), 7.41 - 7.43 (m, 1H), 7.13 - 7.40 (m, 7H), 4.55 (s, 2H), 4.26 (s, 2H), 4.15-4.17 (brd, 1H), 3.50-3.62 (m, 4H), 3.37-3.40 (brd, 1H).

Example 3

4-(4-fluoro-3-(1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one..




10

15 $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 12.74 (s, 1H), 12.58 (s, 1H), 8.25 (d, $J = 7.6$ Hz, 1H), 7.97 (dd, $J = 8$ & 3.6 Hz, 1H), 7.80 - 7.90 (m, 2H), 7.42-7.59 (m, 3H), 7.25 (t, $J = 9$ Hz, 1H), 4.56 (s, 2H), 4.35 (s, 2H), 4.25-4.29 (brd, 2H).

Example 4

15 4-(3-(5-(cyclopropanecarbonyl) octahydropyrrolo [3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one.




15 $^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 12.59 (s, 1H), 8.24 (d, $J = 1.2$ Hz, 1H), 7.96 (dd, $J = 8$ & 4.8 Hz, 1H), 7.82 - 7.90 (m, 2H), 7.40 (dd, $J = 6.8$ & 5.2 Hz, 2H), 7.23 (dd, $J = 9.6$ & 3.6 Hz, 2H), 4.32 (s, 2H), 3.89-3.90 (brt, 1H), 3.70-3.80 (m, 1H), 3.50-3.60 (m,

1H), 3.40-3.49 (m, 2H), 3.22-3.26 (m, 2H), 3.11 – 3.16 (m, 2H), 2.90-3.0 (m, 1H), 1.17-1.25 (m, 1H), 0.69-0.72 (brt, 4H).

Example 5


4-(3-(1-(cyclopropylmethyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d6): δ 12.77 (brs, 1H), 8.30 (d, J = 7.6 Hz, 1H), 8.03 (dd, J = 7.6 & 4.8 Hz, 1H), 7.83-7.91 (m, 2H), 7.46-7.58 (m, 3H), 7.24-7.29 (brt, 1H), 4.57 (s, 2H), 4.37 (s, 2H), 4.25-4.29 (brd, 2H), 4.0 (d, J = 7.2 Hz, 2H), 1.12-1.19 (m, 1H), 0.35-0.47 (m, 4H).

Example 6


4-(3-(5-(cyclopropylmethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, CDCl3): δ 10.30 (s, 1H), 8.44-8.47 (m, 1H), 7.70-7.79 (m, 3H), 7.35 (dd, J = 6.4 & 2.4 Hz, 1H), 7.26-7.31 (m, 1H), 7.0-7.05 (brt, 1H), 4.27 (s, 2H), 3.75-3.76 (brd, 2H), 3.45-3.47 (m, 1H), 2.88-3.24 (m, 4H), 2.36-2.52 (m, 5H), 0.98 (brs, 1H), 0.56-0.58 (brd, 2H), 0.19-0.58 (brd, 2H).

Example 7


20 4-(4-fluoro-3-(5-(2,2,2-trifluoroethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, CDCl_3): δ 10.28 (s, 1H), 8.45-8.47 (m, 1H), 7.70-7.77 (m, 3H), 7.36 (dd, $J=6.4$ & 2.4 , 1H), 7.26-7.29 (m, 1H), 6.99-7.04 (m, 1H), 4.27 (s, 2H), 3.86-3.91 (m, 1H), 3.61-3.65 (m, 1H), 3.48-3.53 (m, 1H), 3.15-3.19 (m, 1H), 3.0-3.07 (m, 1H), 2.86-2.99 (m, 1H), 2.69-2.82 (m, 3H), 2.50-2.53 (m, 1H)

5 **Example 8**


4-(3-(5-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



10 1H NMR (400 MHz, DMSO-d_6): δ 12.59 (s, 1H), 8.27 – 8.25 (m, 1H), 7.97 (d, $J = 7.6$ Hz, 1H), 7.91 – 7.87 (m, 1H), 7.83 (dd, $J = 7.6$ Hz & 1.2 Hz, 1H), 7.42 (dd, $J = 10.4$ Hz & 5.2 Hz, 2H), 7.26 – 7.22 (m, 1H), 4.32 (s, 2H), 4.23 (s, 2H), 3.92 (s, 2H), 3.78 – 3.46 (m, 3H), 3.42 (s, 1H), 2.69 – 2.66 (m, 1H), 1.0 – 0.7 (m, 1H), 0.5 – 0.035 (m, 2H), 0.2 (m, 2H).

15 **Example 9**


15 4-(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride



20 1H NMR (400 MHz, DMSO-d_6): δ 12.62 (s, 1H), 10.81 (s, 1H), 8.26 (m, 1H), 8.32 – 7.98 (m, 1H), 7.87 – 7.61 (m, 1H), 7.59 (dd, 1H), 7.53 (dd, 1H), 7.44 (m, 4H), 7.38 – 7.35 (m, 1H), 7.27 – 7.19 (m, 1H), 4.39 – 4.31 (m, 4H), 3.72 (d, 1H), 3.28 (m, 1H), 3.16 (m, 2H), 2.99 – 2.89 (m, 2H), 2.73 – 2.49 (m, 2H).

Example 10


4-(4-fluoro-3-(5-(2-((3-fluorophenyl)thio)-2-methylpropanoyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d₆): δ 12.58 (s, 1H), 8.25 (d, J = 6.4 Hz, 1H), 7.90 (d, 1H), 7.88 (t, 1H), 7.82 (t, 1H), 7.37 (d, J = 6.4 Hz, 1H), 7.34 (m, 2H), 7.19 (t, 2H), 7.1 (m, 2H), 4.45 (d, 2H), 4.39 (t, 4H), 4.30 (s, 2H), 3.43 – 3.36 (m, 3H), 3.17 (d, 2H), 1.4 (s, 6H).

Example 11


2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione



10 ¹H NMR (400 MHz, DMSO-d₆): δ 12.59 (s, 1H), 8.25 (dd, J = 7.6 Hz & 0.6 Hz, 1H), 7.94 (d, J = 7.6 Hz, 1H), 7.86 – 7.80 (m, 2H), 7.35 (m, 1H), 7.32 (dd, 1H), 5.29 – 7.24 (m, 4H), 7.23 – 7.20 (m, 2H), 4.32 (s, 2H), 3.63 (m, 1H), 3.47 (m, 1H), 3.46 (m, 2H), 3.36 (m, 1H), 2.9 (dd, 1H), 2.60 – 2.8 (m, 3H), 2.51 – 2.49 (m, 2H), 2.1 (m, 1H)

Example 12


15 4-(3-(1-(cyclopropanecarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d₆): δ 12.57-12.60 (brd, 1H), 8.26 (d, J = 7.6 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.69-7.92 (m, 3H), 7.45-7.49 (m, 2H), 7.25-7.30(brt, 1H), 4.80(brs, 2H), 4.37 (brs, 2H), 4.34 (s, 2H), 4.28(brs,1H), 2.97-3.0 (m, 1H), 1.07-1.23 (m, 4H).

Example 13


tert-butyl 5-(2-fluoro-5-((4-oxo-3,4-dihydropthalazin-1-yl)methyl)benzyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate



5 ^1H NMR (400 MHz, DMSO-d6): δ 12.59 (s, 1H), 8.25 (t, J = 8 Hz, 1H), 7.97 (d, J = 8 Hz, 1H), 7.82 – 7.88 (m, 2H), 7.39 – 7.41 (m, 2H), 7.21 – 7.23 (brt, 1H), 4.32 (s, 2H), 3.68 (brs, 1H), 3.50 (brd, 2H), 3.39-3.41 (brd, 2H), 3.00-3.03 (brt, 2H), 2.81-2.89 (brd, 2H), 1.39 (s, 9H).

Example 14


10 4-(4-fluoro-3-(hexahydro-1H-furo[3,4-c]pyrrole-5-carbonyl)benzyl)phthalazin-1(2H)-one



15 ^1H NMR (400 MHz, DMSO-d6): δ 12.59 (s, 1H), 8.26 (dd, J = 7.6 & 0.8 Hz, 1H), 7.97 (d, J = 8 Hz, 1H), 7.80-7.89 (m, 2H), 7.39-7.43 (m, 1H), 8.35 (dd, J = 6.4 & 2 Hz, 1H), 7.19-7.23 (brt, 1H), 4.32 (s, 2H), 3.74-3.78 (m, 1H), 3.64-3.69 (m, 2H), 3.33-3.55 (m, 4H), 3.01-3.02 (m, 2H), 2.91-3.07 (m, 2H).

Example 15


20 4-(4-fluoro-3-(octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d6): δ 12.60 (s, 1H), 8.26 (dd, J = 7.6 & 0.8 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.82 – 7.88 (m, 2H), 7.32 – 7.34 (m, 1H), 7.18 – 7.23 (m, 1H), 4.32 (s, 2H), 3.67-3.72 (m, 1H), 3.30-3.40 (m, 2H), 2.77-2.96 (m, 2H), 2.58-2.73 (m, 4H), 2.41-2.44 (m, 1H).

5 **Example 16**


4-(4-fluoro-3-(5-(methylsulfonyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1H), 8.26 (dd, J = 8 & 1.2 Hz, 1H), 7.96 (d, J = 8 Hz, 1H), 7.82 – 7.89 (m, 2H), 7.39-7.41 (brd, 2H), 7.19-7.24 (m, 1H), 4.32 (s, 2H), 3.69-3.74 (m, 1H), 3.39-3.50 (m, 5H), 2.98-3.15 (m, 4H), 2.91 (s, 3H).

10 **Example 17**


4-(4-fluoro-3-(1-(methylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one



15 1H NMR (400 MHz, DMSO-d6): δ 12.59 (brd, 1H), 8.26 (d, J = 7.6 Hz, 1H), 7.97 (d, J = 8 Hz, 1H), 7.72-7.90 (m, 3H), 7.47-7.50 (m, 2H), 7.29-7.30 (m, 1H), 4.81 (brs, 1H), 4.58 (brs, 2H), 4.34 (brs, 1H), 3.52-3.57 (brd, 3H).

Example 18


20 4-(3-(5-benzoyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d6): δ 12.59 (s, 1H), 8.25 (d, J = 7.2 Hz, 1H), 7.80 – 7.96 (m, 3H), 7.23-7.50 (m, 7H), 7.21-7.23 (m, 1H), 4.30- 4.33 (brd, 2H), 3.38-3.75 (m, 5H).

5 **Example 19**


4-(3-(5-(2,4-difluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, CDCl3): δ 12.59 (s, 1H), 8.44-8.46 (m, 1H), 7.69-7.78 (m, 3H),
10 7.31-7.37 (m, 2H), 7.26-7.29 (m, 1H), 6.99-7.04 (brt, 1H), 6.75-6.86 (m, 2H), 4.27 (s, 2H), 3.83-3.88 (m, 1H), 3.60-3.66 (m, 4H), 3.14-3.18 (m, 1H), 2.51-2.88 (m, 5H), 2.33-2.35 (m, 1H).

Example 20


4-(3-(5,6-dihydro-4H-furo[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d6): δ 12.59 (s, 1H), 8.26 (dd, J = 7.6 Hz & 1.2 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.85 – 7.81 (m, 1H), 7.53 (d, J = 1.2 Hz, 1H), 7.46 – 7.42 (m, 2H), 7.41 – 7.40 (d, J = 1.2 Hz, 1H), 7.28 – 7.23 (m, 20 1H), 4.56 (s, 2H), 4.34 (s, 2H), 4.26 (s, 2H).

Example 21


4-(4-fluoro-3-(5-methyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one



5 ^1H NMR (400 MHz, CDCl_3): δ 9.90 (s, 1H), 8.44-8.47 (m, 1H), 7.70-7.79 (m, 3H),
7.27-7.52 (m, 2H), 6.99-7.04 (brq, 1H), 4.26 (s, 2H), 3.85-3.90 (m, 1H), 3.62-3.64
(m, 1H), 3.44-3.51 (m, 1H), 3.19-3.21 (m, 1H), 2.73-2.97 (m, 4H).

Example 22


10 5-(2-fluoro-5-((4-oxo-3,4-dihydropthalazin-1-yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione



15 ^1H NMR (400 MHz, DMSO-d_6): δ 12.58 (s, 1H), 11.4 (s, 1H), 8.26 (dd, $J = 7.6$ Hz
& 0.8 Hz, 1H), 7.87 – 7.96 (m, 2H), 7.80-7.85 (m, 1H), 7.41-7.43 (m, 1H), 7.37 (dd, J
= 6.4 Hz & 2.4 Hz, 1H), 7.20– 7.24 (brt, 1H), 4.31 (s, 2H), 4.09-4.12 (brd, 1H), 3.38-
3.58 (m, 5H).

Example 23


4-(4-fluoro-3-(octahydrocyclopenta[c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one



¹H NMR (400 MHz, CDCl₃): δ 10.04 (s, 1H), 8.44-8.46 (m, 1H), 7.70-7.77 (m, 3H), 7.24-7.33 (brt, 1H), 7.01-7.03 (m, 1H), 6.99-7.03 (brt, 1H), 4.26 (s, 2H), 3.79-3.84 (m, 1H), 3.43-3.49 (m, 2H), 3.0-3.04 (m, 1H), 2.60-2.72 (m, 2H), 1.49-1.88 (m, 6H).

Example 24


5 4-(4-fluoro-3-(5-(4-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one



10 ¹H NMR (400 MHz, CDCl₃): δ 10.18 (s, 1H), 8.44-8.46 (m, 1H), 7.69-7.76 (m, 3H), 7.33-7.35 (m, 1H), 7.25-7.34 (m, 3H), 6.96-7.04 (m, 3H), 4.27 (s, 2H), 3.83-3.88 (m, 1H), 3.45-3.64 (m, 4H), 3.13-3.17 (m, 1H), 2.80-2.90 (m, 2H), 2.62-2.63 (m, 1H), 2.49-2.52 (m, 2H), 2.28-2.31 (m, 1H).

Example 25

4-(4-fluoro-3-(5-(2-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one




15

10 ¹H NMR (400 MHz, CDCl₃): δ 10.09 (s, 1H), 8.44-8.46 (m, 1H), 7.69-7.76 (m, 3H), 7.34-7.37 (m, 2H), 7.21-7.28 (m, 2H), 6.99-7.12 (m, 3H), 4.26 (s, 2H), 3.84-3.89 (m, 1H), 3.59-3.65 (m, 3H), 3.45-3.50 (m, 1H), 3.14-3.18 (m, 1H), 2.8-2.9 (m, 2H), 2.67-2.69 (m, 1H), 2.53-2.61 (m, 2H), 2.33-2.36 (m, 1H).

20 **Example 26**


4-(4-fluoro-3-(5-(2-(4-(4-fluoro-3-((6-methoxypyridin-2-yl)methyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, CDCl₃): δ 10.19 (s, 1H), 8.43-8.46 (m, 1H), 7.69-7.76 (m, 3H),
 7.51-7.55 (m, 1H), 7.34-7.36 (m, 1H), 7.26-7.28 (m, 1H), 7.0-7.04 (brt, 1H), 6.95 (d,
 J = 6.8 Hz, 1H), 6.60 (d, J = 8.4 Hz, 1H), 4.26 (s, 2H), 3.91 (s, 3H), 3.85-3.91 (m,
 5 1H), 3.18-3.22 (m, 1H), 2.60-2.79 (m, 5H), 2.08-2.44 (m, 1H).

Example 27


5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)-2-methyltetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione



10 1H NMR (400 MHz, DMSO-d₆): δ 10.17 (s, 1H), 8.45-8.47 (m, 1H), 7.74 – 7.82 (m,
 2H), 7.69-7.71 (m, 1H), 7.26-7.34 (m, 2H), 7.02-7.06 (m, 1H), 4.45-4.49 (brd, 1H),
 4.26 (s, 2H), 3.58-3.69 (m, 2H), 3.36-3.46 (m, 2H), 3.0 (s, 3H).

Example 28


Mixture of 4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one compound with 4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one (1:3)



1H NMR (400 MHz, DMSO-d₆): δ 12.59 (s, 1H), 8.24-8.27 (m, 1H), 7.96-7.99 (m,
 20 1H), 7.81-7.90 (m, 2H), 7.43-7.56 (m, 3H), 7.23-7.27 (m, 1H), 4.54 (s, 2H), 4.33 (s,
 2H), 4.23-4.27 (brd, 2H), 3.82 (s, 3H).

Example 29


4-(3-(2,2-dioxido-3,4,5,6-tetrahydro-1H-thieno[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



5 1H NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1H), 8.27 (d, J = 7.6 Hz, 1H), 7.98 (d, J = 8 Hz, 1H), 7.91 (dd, J = 14 Hz & 6.8 Hz, 1H), 7.85 – 7.81 (m, 1H), 7.45 – 7.44 (m, 2H), 7.28 – 7.23 (m, 1H), 4.35 – 4.32 (d, 4H), 4.06 (s, 2H), 4.007 (s, 2H), 3.88 (s, 2H).

Example 30


10 4-(3-(5,6-dihydro-4H-thieno[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



15 1H NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1H), 8.26 (dd, J = 8 Hz & 1.2 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.85 – 7.81 (m, 1H), 7.46 – 7.43 (m, 2H), 7.29 – 7.23 (m, 2H), 7.16 (m, 1H), 4.59 (s, 2H), 4.34 (s, 2H), 4.29 (s, 2H).

Example 31

4-(4-fluoro-3-(1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one




20 1H NMR (400 MHz, DMSO-d6): δ 12.59 (s, 1H), 8.26 (m, J = 7.6Hz & 1.2 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.90 – 7.84 (m, 1H), 7.82 – 7.80 (m, 1H), 7.44 – 7.40 (m,

2H), 7.22 – 7.21 (m, 1H), 4.32 (s, 2H), 4.26 – 4.19 (d, 2H), 3.96 – 3.87 (d, 2H), 3.63 – 3.59 (d, 2H), 3.58 – 3.48 (d, 2H).

Example 32

4-(4-fluoro-3-(5-phenyloctahydronaphthalen-1(2H)-one-2-carbonyl)benzyl)phthalazin-

5 1(2H)-one




1H NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1H), 8.25 (dd, J =7.6 & 1.2 Hz, 1H), 7.95 (d, J =7.6 Hz, 1H), 7.80-7.85 (m, 2H), 7.36-7.42 (m, 2H), 7.14-7.23 (m, 3H), 6.62 (t, J =7.6 Hz, 1H), 6.52 (d, J =8 Hz, 2H), 4.31 (s, 2H), 3.74-3.79 (m, 1H), 3.42-3.48 (m, 10 3H), 3.32-3.36 (m, 1H), 3.18-3.22 (m, 1H), 2.96-3.10 (m, 4H)

Example 33

4-(4-fluoro-3-(5-methyl-1,2,3,4,5,6-hexahydronaphthalen-1(2H)-one-2-carbonyl)


benzyl) phthalazin-1(2H)-one



15 1H NMR (400 MHz, DMSO-d6): δ 12.59 (s, 1H), 8.26 (dd, J =8 Hz & 0.8 Hz, 1H), 7.96 (d, J =7.6 Hz, 1H), 7.90 – 7.86 (m, 1H), 7.84 – 7.80 (m, 1H), 7.43 – 7.40 (m, 2H), 7.25 – 7.21 (m, 1H), 4.32 (s, 2H), 4.19 (s, 2H), 3.58 (s, 2H), 3.43 (s, 2H), 2.42 (s, 3H).

Example 34


20 4-(3-((3aR,8bR)-decahydronaphthalen-1(2H)-one-2-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d6): δ 10.5 – 10.2 (d, 1H), 8.44 – 8.46 (m, 1H), 7.71 – 7.77 (m, 3H), 7.41 – 7.38 (m, 1H), 7.24 (d, J = 2.4 Hz, 1H), 7.02 – 6.99 (m, 1H), 4.24 (s, 2H), 3.89 – 0.88 (m, 15H).

5 **Example 35**


4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, CDCl3): δ 10.02 (s, 1H), 8.44-8.46 (m, 1H), 7.69-7.79 (m, 3H), 10 7.29-7.40 (m, 2H), 7.04-7.17 (m, 2H), 4.73-4.77 (brd, 2H), 4.37-4.39 (brd, 2H), 4.28 (s, 2H), 3.89-3.90 (brd, 2H).

Example 36

4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one




15

1H NMR (400 MHz, CDCl3): δ 9.98 (s, 1H), 8.44-8.47 (m, 1H), 7.70-7.80 (m, 3H), 7.31-7.40 (m, 2H), 7.06-7.30 (m, 2H), 4.72-4.78 (brd, 2H), 4.37-4.44 (brd, 2H), 4.28-4.29 (brd, 2H), 3.73-3.85 (brd, 3H).

Example 37


20 2-((5-(2-fluoro-5-((4-oxo-3,4-dihydropthalazin-1-yl)methyl)benzoyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)-6-methoxypyridine-1-oxide



1H NMR (400 MHz, DMSO-d6): δ 12.70 (s, 1H), 8.26 (d, J = 8.8 Hz, 1H), 8.83-8.91 (m, 3H), 7.67-7.70 (m, 1H), 7.41-7.45 (m, 1H), 7.28-7.30 (m, 1H), 7.16-7.23 (m, 1H), 6.82 (d, J = 8 Hz, 1H), 4.40-4.41 (brd, 2H), 4.31 (s, 2H), 3.82 (s, 3H), 3.70-3.73 (brd, 5 H), 3.37-3.47 (m, 3H), 3.12-3.25 (m, 3H), 2.99-3.02 (brd, 1H).

Example 38


4-(3-(5-(difluoromethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, CDCl3): δ 10.25 (s, 1H), 8.45-8.47 (m, 1H), 8.21-8.24 (m, 1H), 7.71-7.79 (m, 3H), 7.30-7.32 (m, 1H), 7.26-7.29 (m, 1H), 7.01-7.05 (m, 1H), 4.27 (s, 2H), 3.87-3.93 (m, 1H), 3.73-3.82 (m, 1H), 3.56-3.70 (m, 1H), 3.46-3.50 (m, 1H), 3.30-3.34 (m, 1H), 3.18-3.23 (m, 1H), 2.92-2.95 (m, 1H).

Example 39

4-(4-fluoro-3-((3aR,6aS)-5-oxooctahydrocyclopenta[c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one




1H NMR (400 MHz, CDCl3): δ 10.63 (s, 1H), 8.47-8.49 (m, 1H), 7.72-7.81 (m, 3H), 7.37-7.39 (m, 1H), 7.30-7.33 (m, 1H), 7.02-7.04 (brt, 1H), 4.30 (s, 2H), 3.95-4.00

(m, 1H), 3.55-3.65 (m, 2H), 3.18-3.22 (m, 1H), 2.94-3.10 (m, 2H), 2.44-2.61 (m, 2H), 2.22-2.28 (m, 1H), 2.08-2.18 (m, 1H).

Example 40

Mixture of 1 & 2 Ethyl 4-(3-(2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-

5 fluorobenzyl)phthalazin-1(2H)-one




1H NMR (400 MHz, DMSO-d6): δ 12.60 (s, 1H), 8.25 (t, 1H), 7.99 (dd, J = 7.6 Hz & 4 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.85 – 7.81 (m, 1H), 7.61 – 7.42 (m, 3H), 7.28 – 7.23 (m, 1H), 5.31 (s, 1H), 4.55 (d, 1H), 4.52 – 4.43 (d, 2H), 4.34 (s, 2H), 4.28 – 10 4.20 (t, 2H), 4.14 – 4.08 (m, 2H), 3.39 – 3.35 (m, 2H), 1.67 – 1.10 (m, 6H).

Example 41

4-(3-(2-ethyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)


phthalazin-1(2H)-one



15 1H NMR (400 MHz, DMSO-d6): δ 12.59 (s, 1H), 8.26 (d, J = 8 Hz, 1H), 7.98 (d, J = 7.6 Hz, 1H), 7.88 (d, J = 8 Hz, 1H), 7.84 (d, J = 7.6 Hz, 1H), 7.61 (s, 1H), 7.46 (d, J = 5.6 Hz, 2H), 5.25 (m, 1H), 4.55 (s, 2H), 4.33 (s, 2H), 4.26 (d, 2H), 4.10 (q, 2H), 1.36 – 1.32 (m, 3H).

Example 42


20 4-(3-(1-ethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d6): δ 10.37 – 10.34 (d, 2H), 8.47 – 8.45 (dd, 1H), 7.82 – 7.22 (m, 3H), 7.41 – 7.33 (m, 2H), 7.20 (s, 1H), 7.13 – 6.99 (m, 1H), 4.82 (s, 1H), 4.72 (s, 1H), 4.46 (s, 1H), 4.37 (s, 1H), 4.37 – 4.31 (d, 2H), 4.15 (q, 2H), 1.48 (t, 2H), 1.37 (t, 1H).

Example 43


4-(4-fluoro-3-(1-isopropyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d6): δ 12.56 (s, 1H), 8.24 (d, J = 7.6 Hz, 1H), 7.95 (t, 1H), 7.87 (t, 1H), 7.81 (t, 1H), 7.46 – 7.42 (m, 2H), 7.27 – 7.22 (m, 1H), 7.15 (s, 1H), 4.74 (s, 1H), 4.48 (s, 1H), 4.45 (m, 1H), 4.32 (s, 2H), 4.30 – 4.26 (m, 1H), 4.16 (s, 1H), 1.37 (d, 3H), 1.23 (t, 3H).

Example 44

Mixture of (1 & 2 isopropyl) 4-(4-fluoro-3-(1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one




1H NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1H), 8.26 (d, J = 7.6 Hz, 1H), 7.98 (d, J = 8 Hz, 1H), 7.91 – 7.81 (m, 2H), 7.48 – 7.42 (m, 2H), 7.29 – 7.23 (m, 1H), 7.17 (s,

1H), 4.55 (s, 1H), 4.49 – 4.44 (m, 1H), 4.33 (s, 2H), 4.29 (s, 1H), 4.24 (s, 1H), 1.40 (dd, 5H), 1.25 (t, 1H).

Example 45


4-(4-fluoro-3-(2-isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one



1H NMR (400 MHz, DMSO-d6): δ 12.57 (s, 1H), 8.26 (d, $J = 7.6$ Hz & 1.2 Hz, 1H), 7.98 (t, 1H), 7.91 – 7.87 (m, 1H), 7.85 – 7.81 (m, 1H), 7.64 – 7.50 (d, 1H), 7.46 – 7.42 (m, 2H), 7.27 (t, 1H), 4.55 (s, 2H), 4.49 – 4.46 (m, 1H), 4.33 (s, 2H), 4.29 (s, 1H), 4.24 (s, 1H), 1.40 – 1.38 (dd, 6H).

Example 46


4-((3a*R*,6a*S*)-5,5-difluorooctahydrocyclopenta[c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



1H NMR (400 MHz, CDCl3): δ 10.07 (s, 1H), 8.45-8.47 (m, 1H), 7.70-7.79 (m, 3H), 7.35-7.37 (m, 1H), 7.24-7.31 (m, 1H), 7.01-7.05 (brt, 1H), 4.27 (s, 2H), 3.82-3.87 (m, 1H), 3.65-3.70 (m, 1H), 3.51-3.56 (m, 1H), 3.18-3.22 (m, 1H), 2.80-2.94 (m, 2H), 2.26-2.45 (m, 2H), 1.87-2.08 (m, 2H).

Example 47


20 4-(4-fluoro-3-(5-(2-methoxyethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one



1H NMR (400 MHz, CDCl3): δ 10.25 (s, 1H), 8.44-8.47 (m, 1H), 7.71-7.79 (m, 3H), 7.34-7.36 (m, 1H), 7.26-7.30 (m, 1H), 6.99-7.04 (brt, 1H), 4.27 (s, 2H), 3.64-3.79 (m, 2H), 3.50-3.53 (m, 2H), 3.42-3.47 (m, 1H), 3.36 (s, 3H), 3.16-3.18 (brd, 1H), 2.80-2.97 (m, 2H), 2.64-2.68 (m, 2H), 2.41-2.42 (brd, 1H).

Example 48


N-((3a*R*,6a*S*)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)octahydrocyclopenta[c]pyrrol-5-yl)cyclopropanecarboxamide



1H NMR (400 MHz, CDCl3): δ 10.38 (s, 1H), 8.44-8.46 (m, 1H), 7.72-7.78 (m, 3H), 7.42-7.44 (m, 1H), 7.26-7.29 (m, 1H), 6.98-7.03 (brt, 1H), 5.57 (brd, 1H), 4.40-4.42 (m, 1H), 4.27 (s, 2H), 3.79-3.85 (m, 1H), 3.48-3.60 (m, 2H), 3.06-3.10 (m, 1H), 2.78-2.85 (m, 2H), 1.90-2.00 (m, 1H), 1.70-1.88 (m, 1H), 1.00-1.03 (m, 2H), 0.83-0.90 (m, 1H), 0.73-0.75 (m, 2H)

Example 50

4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one hydrobromide




1H NMR (400 MHz, DMSO-d6): δ 12.59 (d, J = 3.6 Hz, 1H), 8.26 (d, J = 7.6 Hz, 1H), 8.005 - 7.92 (m, 1H), 7.911 - 7.87 (m, 1H), 7.85 - 7.81 (m, 1H), 7.48 - 7.43 (m,

2H), 7.30 – 7.25 (m, 1H), 7.15 (brs, 1H), 4.69 (s, 1H), 4.53 (s, 1H), 4.42 (s, 1H), 4.34 (s, 2H), 4.21 (s, 1H), 3.78 – 3.66 (brd, 3H).

Example 51

4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)

5 phthalazin-1(2H)-one hydrochloride




1H NMR (400 MHz, DMSO-d6): δ 12.59-12.59 (d, J = 3.6Hz, 1H), 8.26 (d, J = 7.6Hz, 1H), 7.98 (t, J = 8Hz, 1H), 7.89 (t, J = 3.4Hz, 1H), 7.83 (t, J = 7.4Hz, 1H), 7.43-7.48 (m, 2H), 7.26-7.28 (m, 1H), 7.15-7.27 (brd, 1H), 4.53-4.69 (brd, 2H), 4.34 (s, 2H), 4.21-4.42 (brd, 2H), 3.66-3.78 (brd, 3H).

Example 52

4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)

phthalazin-1(2H)-one sulfate




15 1H NMR (400 MHz DMSO-d6): δ 12.59-12.58 (d, J = 3.2Hz, 1H), 8.26 (d, J = 8Hz, 1H), 7.97 (m, 1H), 7.89 (m, 1H), 7.84 (m, 1H), 7.48-7.43 (m, 2H), 7.15 (s, 1H), 4.53 (s, 1H), 4.41 (s, 1H), 4.34 (s, 2H), 4.21 (s, 1H), 3.78 (s, 3H), 3.73 (m, 1H).

Example 53

4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)


20 phthalazin-1(2H)-one 4-methylbenzenesulfonate



1H NMR (400 MHz, DMSO-d6): δ 12.59-12.58 (d, J = 3.2Hz, 1H), 8.26 (d, J = 7.6Hz, 1H), 7.98 (m, 1H), 7.904 (m, 1H), 7.87-7.81 (m, 1H), 7.48-7.43 (m, 4H), 7.3-7.28 (m, 1H), 7.11 (m, 2H), 4.69 (s, 1H), 4.53 (s, 1H), 4.41 (s, 1H), 4.21 (s, 1H), 3.72 (s, 3H), 2.28 (s, 3H)


5 **Example 54**

4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one benzenesulfonate



1H NMR (400 MHz, DMSO-d6): δ 12.59-12.59 (d, J = 3.2Hz, 1H), 8.26 (d, J = 8Hz, 1H), 7.87-7.92 (m, 1H), 7.83 (t, J = 7.6Hz, 1H), 7.58-7.61(m, 2H), 7.43-7.48 (m, 2H), 7.15-7.34 (m, 7H), 4.53-4.69 (brd, 2H), 4.34 (s, 2H), 4.21-4.41 (brd, 2H), 3.66-3.78 (brd, 3H).


10 **Example 55**
 15 5-(2-fluoro-5-((4-oxo-3,4-dihydropthalazin-1-yl)methyl)benzoyl)-2-isopropyl-
 20 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-2-ium hydrogensulfate



1H NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1H), 8.26 (dd, J = 8 Hz & 1.2 Hz, 1H), 7.98 (dd, J = 7.6 Hz & 2.4 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.85 – 7.81 (m, 1H), 7.64 – 7.51 (brd, 1H), 7.47 – 7.42 (m, 2H), 7.28 – 7.23 (m, 1H), 4.55 (s, 2H), 4.51 – 4.45 (m, 1H), 4.33 (s, 2H), 4.29 – 4.24 (brd, 2H), 1.40 – 1.38 (brd, 4H).

20 **Example 56**


4-(3-(1-cyclopropyl-1,4,5,6-tetrahydropyrrolo [3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one




¹H NMR (400 MHz, DMSO-*d*₆): δ 12.58 (d, *J* = 2.4 Hz, 1H), 8.24 (d, *J* = 7.6 Hz, 1H), 7.98 – 7.37 (m, 1H), 7.89 – 7.85 (m, 1H), 7.81 (t, 1H), 7.47 – 7.39 (m, 2H), 7.28 – 7.22 (m, 1H), 7.14 (d, 1H), 4.70 (s, 1H), 4.48 (s, 1H), 4.42 (s, 1H), 4.32 (s, 2H), 4.16 (s, 1H), 3.57 – 3.44 (m, 5H), 1H), 0.98 – 0.82 (m, 4H).

The following compounds can be synthesized following the same procedure as described for example 1 and are considered to be encompassed within the scope of the present invention.


10 4-(4-fluoro-3-(1-propyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one




2-(cyclopropanecarbonyl)-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione




15 5-(cyclopropanecarbonyl)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione




4-(4-fluoro-3-(2-(trifluoromethyl)-5,6-dihydro-4H-pyrrolo[3,4-d]oxazole-5-carbonyl)benzyl)phthalazin-1(2H)-one



5 4-(3-(2-(cyclopropanecarbonyl)-5,6-dihydro-4H-pyrrolo[3,4-d]oxazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one




4-(4-fluoro-3-(2-(trifluoromethyl)-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]thiazole-5-carbonyl)benzyl)phthalazin-1(2H)-one




10


5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)dihydro-1H-furo[3,4-c]pyrrole-4,6(5H,6aH)-dione




5-(cyclopropanecarbonyl)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)pyrrolo[3,4-c]pyrrole-1,3(2H,5H)-dione




4-(3-(5-benzyl-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one




5-(cyclopropylmethyl)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)pyrrolo[3,4-c]pyrrole-1,3(2H,5H)-dione



10 4-(3-(5-(cyclopropanecarbonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one



2-(cyclopropylmethyl)-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione



Biological activity- *In vitro* study**In vitro study**

Potentiation of cell killing activity of Methyl Methane Sulphonate (MMS) by selected compounds according to present invention was evaluated in MCF-7 cell line obtained

5 from National Centre for Cell Science, Pune, by using MTT assay according to general protocol described in *Methods in Molecular Biology, Volume-43, In vitro Toxicity Testing Protocol, Chapter-6, page:137-149*. Compounds were tested for PARP 1 activity based on percent cell survival of MCF-7 cells with alkylating agent MMS.

10 The compounds were tested for PARP-1 inhibitory activity by using HT universal colorimetric PARP assay kit obtained from Trevigen, following manufacturer's protocol.

The results of the compounds are provided in Table 1.

Result of Table 1 shows that the compounds are found to possess PARP 1 inhibitory

15 activity, thus have potential to be developed as compounds for therapeutic use.

In vivo study

On basis of the in vitro data, the ability of selected compounds to potentiate the antitumor activity of the methylating chemotherapeutic agent, temozolomide, was evaluated in an SW 620 tumor model.

20 Animals bearing SW 620 xenograft tumors were treated with the compounds in combination with TMZ (50 mg/Kg, po) once daily for 5 consecutive days, after which the tumors were left to grow out. A considerable inhibition of tumor volumes as compared with that of the TMZ alone group was observed for the TMZ plus compounds combinations (mean values given as relative tumor volumes (RTV) [table 2]. The compounds did not exacerbate the systemic toxicity of TMZ, with a maximum mean body weight loss of 9-10% on day 6 with full recovery of body weight within 3 days and with no mortalities, which indicates that the combination therapy was well tolerated by compounds under the dosing regimen.

30 Female athymic nude mice were used for antitumor *in vivo* studies. SW620 colorectal tumor cells (1×10^7 cells per animal) were implanted s.c. into one flank of each mouse. When tumors were palpable (10-12 days after implantation), animals were treated (n= 6-8/group) with five daily doses of temozolomide administered per os as a

suspension in 0.5% methyl cellulose at 50 mg/kg either alone or in combination with a five daily per os administrations of PARP inhibitor at different doses. Tumor growths were measured using two-dimensional caliper measurements. Tumor volume was calculated using the equation $a^2 \times b / 2$, where a is the smallest measurement and 5 b is the largest. Data are presented as median relative tumor volumes (RTV), defined as the calculated tumor volume divided by the calculated tumor volume on the initial day of treatment (day 0). Thus, on day 0, the RTV value is 1 and RTV4 is when the tumor is four times as large as its initial value. Control animals were treated with vehicle (15 tween 80 in methyl cellulose) alone tumor growth delay (TGD) = Time to 10 RTV4 in treated group - time to RTV4 control.

Table 1: In-Vitro PARP-1 activity

Compound	PARP-1 activity in vitro IC50(nM) ^a	Compound	PARP-1 activity in vitro IC50(nM) ^a
Olaparib	8.39 \pm 2.3	Compound 29	18.43
Compound 1	11.54	Compound 30	9.87
Compound 2	8.41	Compound 31	24.25
Compound 3	14.55	Compound 32	11.54
Compound 6	46.71	Compound 33	28.5
Compound 7	38.63	Compound 34	11.68
Compound 9	23.97	Compound 35	29.87
Compound 12	14.15	Compound 36	27.87
Compound 14	46.45	Compound 38	90.95
Compound 15	11.64	Compound 39	54.52
Compound 16	103.8	Compound 40	9.9
Compound 17	30.27	Compound 41	8.9
Compound 19	34.41	Compound 42	48.6
Compound 20	11.78	Compound 43	55.1
Compound 21	22.56	Compound 44	19.87
Compound 22	20.22	Compound 45	13.8
Compound 23	67.85	Compound 46	27.8
Compound 24	9.85	Compound 47	48.3
Compound 25	27.81	Compound 48	74.5
Compound 26	35.95	Compound 54	15.4
Compound 27	12.47	Compound 55	13.23
Compound 28	20.73		

^a PARP 1 IC₅₀ are estimation as calculated from a 4 point dose response curve

Table 2: In vivo antitumor efficacy of compounds in combination with temozolomide (TMZ) in an SW620 tumor model ^b.

Compounds	Median time to RTV4(days)	Tumor growth delay(days)
Vehicle(control)	10	
Temozolomide (50 mg/kg, po)	22	12
TMZ (50 mg/kg, po) + example 20 (50 mg/kg, po)	43	33
TMZ (50 mg/kg, po) + example 35 (10 mg/kg, po)	50	40
TMZ (50 mg/kg, po) + example 36 (10 mg/kg, po)	37	27
TMZ (50 mg/kg, po) + example 36 (30 mg/kg, po)	44	34
TMZ (50 mg/kg, po) + example 36 (100 mg/kg, po)	65	55

⁵ ^b Mice were orally dosed once daily for 5 consecutive days. The compounds were administered 45 min before TMZ.


10

15

20

We Claim:

1. Compound having the structure of general formula (I)



5 wherein 'A' and 'B' is independently selected from hydrogen, alkyl or connected together to the carbon atoms to form a cycloalkyl, heterocyclyl, aryl or heteroaryl groups, R¹ at each occurrence is independently selected from H, halogen, or the groups selected from (C₁-C₁₂)alkyl, haloalkyl, cycloalkyl, alkylthio or the group (OSO₂) alkyl, wherein each of these groups are further optionally substituted with
10 suitable substituents;

m = 1-4; L = -O, -S, -NH;
R² is selected from substituent groups consisting of hydrogen atom, hydroxyl, alkyl, cycloalkyl, oxo, C(O)OR⁵, -C(O)R⁵, or -C(O)NR⁶R⁷, wherein said alkyl and cycloalkyl groups are further substituted by one or more substituents
15 selected from halogen, hydroxyl, alkyl or alkoxy groups;


R³ and R⁴ are each independently selected from hydrogen atom, alkyl, hydroxyl, alkoxy, cycloalkyl, -C(O)OR⁵, -OC(O)R⁵, -O(CH₂)_pC(O)OR⁵, -C(O)R⁵, -NHC(O)R⁵, -NR⁶R⁷, -OC(O)NR⁶R⁷ or -C(O)NR⁶R⁷ or alternatively, R³ and R⁴ together forms an oxo group;

20 Each of ring atoms 'D' and 'E' is independently selected from C or N atoms;
'D' and 'E' are connected to one another to form 5 membered ring 'X', wherein 'X' is selected from cycloalkyl, heterocyclyl, heteroaryl, wherein the cycloalkyl, heterocyclyl, heteroaryl is further substituted with one or more suitable substituents;


25 R⁵ at each occurrence is independently selected from hydrogen atom, optionally substituted groups selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl

groups; Each of R⁶ or R⁷ at each occurrence are independently selected from H, optionally substituted groups selected from hydrogen atom, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. Alternatively, R⁶ and R⁷ are joined together with nitrogen atom to form a heterocyclyl ring; wherein said heterocyclyl ring contains 5 one or more heteroatoms selected from N, O, S(O)_n, n is 0, 1 or 2 and p is 0, 1 or 2.

2. The compound as claimed in claim 1, wherein heterocycles representing



is selected from the following bicyclic rings mentioned below



10

3. The compound as claimed in claim 1 wherein the substituents on the ring formed by A & B taken together is independently selected from one or more substituent groups selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, 15 aryl, heteroaryl, -C(O)OR⁵, -OC(O)R⁵, -O(CH₂)_pC(O)OR⁵, -C(O)R⁵, -NHC(O)R⁵, -NR⁶R⁷, -OC(O)NR⁶R⁷ or -C(O)NR⁶R⁷ wherein each of R⁵, R⁶ & R⁷ are as defined in claim 1.


4. The compound as claimed in claim 1, wherein the substituents on R¹ is selected from hydroxyl, oxo, halo, thio, nitro, amino, alkyl, alkoxy, haloalkyl or 20 haloalkoxy groups alone or in combination with other radicals.


5. The compound as claimed in claim 1 wherein the substituents on R⁵ is selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents.
6. The compound as claimed in claim 1 wherein the substituents on R⁶ & R⁷ at each occurrence is independently selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents.
7. The compound as claimed in claim 1, wherein the substituents on ring X is selected from halogen, hydroxyl, oxo, optionally substituted groups selected from alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, benzyl, OR⁵, -C(O)OR⁵, -OC(O)R⁵, -O(CH₂)_pC(O)OR⁵, C(O)R⁵, S(O)_nR⁵, -NHC(O)R⁵, NR⁶R⁷, -OC(O)NR⁶R⁷ or -C(ONR⁶R⁷), wherein each of R⁵, R⁶ & R⁷ are as defined in claim 1 and wherein the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or benzyl group are each independently substituted further with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -C(O)OR⁵, -OC(O)R⁵, O(CH₂)_pC(O)OR⁵, -C(O)R⁵, -S(O)_nR⁵, -NHC(O)R⁵, NR⁶R⁷, -OC(O)NR⁶R⁷ or -C(ONR⁶R⁷) groups.
8. The compound as claimed in claim 1, wherein “aryl” groups is selected from phenyl, naphthyl, tetrahydronaphthyl, indenyl, dihydroindenyl, biphenyl groups.
- 20 9. The compound as claimed in claim 1, wherein the substituents on aryl groups are independently selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, cyano, thioalkyl, cycloalkyl groups.
10. The compound as claimed in claim 1, wherein the heteroaryl or heteroaromatic group is selected from pyridyl, thienyl, furyl, pyrrolyl, indolyl, indolyl, 25 pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, purinyl groups.
11. The compound as claimed in claim 1, where in the substitution on heteroaryl or heteroaromatic group is selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups.
- 30 12. The compound as claimed in claim 1, wherein the heterocyclyl group is selected from aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2-oxopiperazinyl, 3-oxopiperazinyl,


morpholinyl, thiomorpholinyl, 2-oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazolidinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidonyl, azaquinazolinoyl, thienopyrimidonyl, quinazolonyl, pyrimidonyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, thienopiperidinyl, groups.


5 13. The compound as claimed in claim 1, wherein the substituents on heterocyclyl group is selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups.


10 14. A compound as claimed in claim 1 selected from the group comprising of:



















8. The compound as claimed in any preceding claim preferably selected from the group comprising of:











15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) as claimed in any of the preceding claims and

optionally one or more pharmaceutically acceptable carriers, diluents or excipients.

16. A method of treating diseases medicated by the PARP-1 protein which comprising administering to a patient in need thereof an effective amount of a compound of Formula (I) as claimed in any of the preceding claims or its suitable pharmaceutical composition.
17. A pharmaceutical composition comprising compound of formula (I) along with suitable excipients suitable for the treatment of diseases through the inhibition of poly (ADP-ribose) polymerase-1.
18. A medicine for the treatment of diseases medicated by the PARP-1 protein which comprises administering a therapeutically effective amount of compound of Formula (I) or its pharmaceutical composition as defined in any of the preceding claims to a patient or subject in need thereof.
19. The use of the compound of formula (I) or its pharmaceutical composition as claimed in any of the preceding claims for the manufacture of a medicament for the inhibition of poly (ADP-ribose) polymerase-1.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IN2013/000794

A. CLASSIFICATION OF SUBJECT MATTER				
INV. C07D237/32 C07D487/04 C07D491/048 C07D495/04 C07D498/04 C07D513/04 A61K31/502 A61P35/00				
ADD.				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols)				
C07D A61K A61P				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)				
EPO-Internal				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages			Relevant to claim No.
X	WO 2012/019426 A1 (SHANGHAI HENGRI PHARM CO LTD [CN]; JIANGSU HENGRI MEDICINE CO [CN];) 16 February 2012 (2012-02-16) cited in the application Many examples the whole document			1-20
A	WO 2012/019427 A1 (SHANGHAI HENGRI PHARM CO LTD [CN]; JIANGSU HENGRI MEDICINE CO [CN];) 16 February 2012 (2012-02-16) cited in the application the whole document			1-20
A	WO 2009/093032 A1 (ASTRAZENECA AB [SE]; MENEAR KEITH ALLAN [GB]; JAVAID MUHAMMAD HASHIM [) 30 July 2009 (2009-07-30) cited in the application the whole document			1-20
				- / --
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.		<input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed				
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family				
Date of the actual completion of the international search		Date of mailing of the international search report		
15 April 2014		28/04/2014		
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Sarakinos, Georgios		

INTERNATIONAL SEARCH REPORT

International application No PCT/IN2013/000794

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2012/071684 A1 (SHANGHAI DE NOVO PHARMATECH CO LTD [CN]; GAO DAXIN [CN]) 7 June 2012 (2012-06-07) cited in the application the whole document -----	1-20
A	US 2005/059663 A1 (MARTIN NIALL MORRISON BARR [GB] ET AL) 17 March 2005 (2005-03-17) the whole document -----	1-20
A	WO 2009/004356 A1 (ASTRAZENECA AB [SE]; JAVAID MUHAMMAD HASHIM [GB]; MENEAR KEITH ALLAN []) 8 January 2009 (2009-01-08) the whole document -----	1-20
A	WO 2009/063244 A1 (ANGELETTI P IST RICHERCHE BIO [IT]; BRANCA DANILA [IT]; DESSOLE GABRIE) 22 May 2009 (2009-05-22) the whole document -----	1-20
A	US 2008/269234 A1 (GANDHI VIRAJKUMAR B [US] ET AL) 30 October 2008 (2008-10-30) the whole document -----	1-20
A	WO 2008/083027 A1 (ABBOTT LAB [US]; GANDHI VIRAJ B [US]; GIRANDA VINCENT L [US]; GONG JIA) 10 July 2008 (2008-07-10) the whole document -----	1-20
A	WO 2007/138351 A2 (ANGELETTI P IST RICHERCHE BIO [IT]; JONES PHILIP [IT]; KINZEL OLAF [IT]) 6 December 2007 (2007-12-06) the whole document -----	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IN2013/000794

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2012019426	A1	16-02-2012	CN	102372706 A		14-03-2012
			CN	102666539 A		12-09-2012
			WO	2012019426 A1		16-02-2012
<hr/>						
WO 2012019427	A1	16-02-2012	AU	2011288876 A1		31-01-2013
			CA	2806324 A1		16-02-2012
			CN	102372716 A		14-03-2012
			CN	102686591 A		19-09-2012
			EP	2604610 A1		19-06-2013
			JP	2013535491 A		12-09-2013
			KR	20130110149 A		08-10-2013
			US	2013131068 A1		23-05-2013
			WO	2012019427 A1		16-02-2012
<hr/>						
WO 2009093032	A1	30-07-2009	AR	070221 A1		25-03-2010
			AU	2009207498 A1		30-07-2009
			CA	2708175 A1		30-07-2009
			CN	101925595 A		22-12-2010
			CO	6290715 A2		20-06-2011
			DO	P2010000219 A		15-08-2010
			EA	201070523 A1		28-02-2011
			EC	SP10010349 A		31-08-2010
			EP	2231638 A1		29-09-2010
			JP	2011510056 A		31-03-2011
			KR	20100116187 A		29-10-2010
			NZ	585982 A		22-12-2011
			PE	13352009 A1		04-10-2009
			SV	2010003625 A		20-05-2011
			TW	200936577 A		01-09-2009
			US	2009192156 A1		30-07-2009
			US	2012129855 A1		24-05-2012
			UY	31603 A1		31-08-2009
			WO	2009093032 A1		30-07-2009
<hr/>						
WO 2012071684	A1	07-06-2012	AU	2010364807 A1		30-05-2013
			CA	2819410 A1		07-06-2012
			CN	103237799 A		07-08-2013
			EP	2646428 A1		09-10-2013
			JP	2013544261 A		12-12-2013
			KR	20130089264 A		09-08-2013
			US	2013224107 A1		29-08-2013
			WO	2012071684 A1		07-06-2012
<hr/>						
US 2005059663	A1	17-03-2005	US	2005059663 A1		17-03-2005
			US	2006149059 A1		06-07-2006
<hr/>						
WO 2009004356	A1	08-01-2009	AR	067460 A1		14-10-2009
			AU	2008272667 A1		08-01-2009
			CA	2691459 A1		08-01-2009
			CL	19832008 A1		24-10-2008
			CN	101848898 A		29-09-2010
			CO	6251253 A2		21-02-2011
			CR	11181 A		20-07-2010
			DO	P2009000288 A		31-03-2010
			EA	200971100 A1		30-06-2010
			EC	SP099813 A		29-01-2010
			EP	2176237 A1		21-04-2010
			JP	2010532339 A		07-10-2010

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IN2013/000794

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
		KR	20100044816 A		30-04-2010
		SV	2009003437 A		17-05-2010
		TW	200908980 A		01-03-2009
		US	2009023727 A1		22-01-2009
		WO	2009004356 A1		08-01-2009
<hr/>					
WO 2009063244	A1	22-05-2009	AU	2008322676 A1	22-05-2009
			CA	2704714 A1	22-05-2009
			CN	101855221 A	06-10-2010
			EP	2220073 A1	25-08-2010
			JP	2011503166 A	27-01-2011
			KR	20100087220 A	03-08-2010
			NZ	585395 A	30-03-2012
			RU	2010123874 A	20-12-2011
			US	2010261709 A1	14-10-2010
			WO	2009063244 A1	22-05-2009
<hr/>					
US 2008269234	A1	30-10-2008	NONE		
<hr/>					
WO 2008083027	A1	10-07-2008	AU	2007340020 A1	10-07-2008
			BR	PI0722070 A2	08-04-2014
			CA	2672868 A1	10-07-2008
			CN	101641014 A	03-02-2010
			CN	103690542 A	02-04-2014
			CO	6220961 A2	19-11-2010
			CR	10901 A	23-07-2009
			DK	2120579 T3	03-02-2014
			EC	SP099530 A	28-08-2009
			EP	2120579 A1	25-11-2009
			EP	2698062 A1	19-02-2014
			ES	2442496 T3	11-02-2014
			GT	200900182 A	19-02-2010
			HR	P20140115 T1	14-03-2014
			JP	2010514785 A	06-05-2010
			JP	2014001209 A	09-01-2014
			KR	20090094116 A	03-09-2009
			NZ	577348 A	27-04-2012
			NZ	598352 A	30-08-2013
			PT	2120579 E	17-02-2014
			RU	2009128984 A	10-02-2011
			SG	193664 A1	30-10-2013
			SI	2120579 T1	31-03-2014
			TW	200840579 A	16-10-2008
			US	2008161280 A1	03-07-2008
			WO	2008083027 A1	10-07-2008
<hr/>					
WO 2007138351	A2	06-12-2007	AU	2007266836 A1	06-12-2007
			BR	PI0711741 A2	06-12-2011
			CA	2653529 A1	06-12-2007
			CN	101501006 A	05-08-2009
			CN	103420988 A	04-12-2013
			EP	2029551 A2	04-03-2009
			JP	5351755 B2	27-11-2013
			JP	2009538896 A	12-11-2009
			KR	20090015092 A	11-02-2009
			NZ	572815 A	25-11-2011
			RU	2008152824 A	10-07-2010
			US	2009176765 A1	09-07-2009

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IN2013/000794

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		WO 2007138351 A2 ZA 200809238 A	06-12-2007 30-12-2009